Emmaus Life Sciences Overview
- Year Founded
-
2000
- Status
-
Public
- Employees
-
33
- Stock Symbol
-
EMMA
- Investments
-
6
- Share Price
-
$0.01
- (As of Thursday Closing)
Emmaus Life Sciences General Information
Description
Emmaus Life Sciences Inc is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sales of the Company's product Endari (prescription grade L-glutamine oral powder), to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Endari is reimbursable by the Centers for Medicare and Medicaid Services, and every state provides coverage for Endari for outpatient prescriptions to all eligible Medicaid enrollees within their state Medicaid programs. Endari is also reimbursable by many commercial payors.
Contact Information
Website
www.emmausmedical.comCorporate Office
- 21250 Hawthorne Boulevard
- Suite 800
- Torrance, CA 90503
- United States
Corporate Office
- 21250 Hawthorne Boulevard
- Suite 800
- Torrance, CA 90503
- United States
Emmaus Life Sciences Stock Performance
As of 12-Nov-2026, Emmaus Life Sciences’s stock price is $0.01. Its current market cap is $1.05M with 70.2M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.01 | $0.02 | $1.05M | 70.2M | 152K | -$0.09 |
Emmaus Life Sciences Financials Summary
As of 30-Jun-2026, Emmaus Life Sciences has a trailing 12-month revenue of $15.5M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 31,909 | 32,306 | 32,349 | 39,199 |
| Revenue | 15,530 | 12,453 | 16,653 | 29,597 |
| EBITDA | 2,316 | (580) | (1,188) | 2,942 |
| Net Income | (6,023) | (7,492) | (6,453) | (3,733) |
| Total Assets | 16,370 | 21,436 | 23,602 | 35,179 |
| Total Debt | 30,516 | 32,559 | 32,963 | 33,424 |
Emmaus Life Sciences Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Emmaus Life Sciences Comparisons
Industry
Financing
Details
Emmaus Life Sciences Competitors (46)
One of Emmaus Life Sciences’s 46 competitors is Renova Therapeutics, a Venture Capital-Backed company based in Carlsbad, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Renova Therapeutics | Venture Capital-Backed | Carlsbad, CA | ||||
| Vanda Pharmaceuticals | Formerly VC-backed | Washington, DC | ||||
| Supernus | Formerly VC-backed | Rockville, MD | ||||
| Dicerna Pharmaceuticals | Formerly VC-backed | Lexington, MA | ||||
| Genentech | Formerly VC-backed | South San Francisco, CA |
Emmaus Life Sciences Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Emmaus Life Sciences Patents
Emmaus Life Sciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20250041291-A1 | Compositions and methods for treating cancer | Pending | 06-Dec-2021 | ||
| WO-2023107145-A1 | Compositions and methods for treating cancer | Inactive | 06-Dec-2021 | ||
| EP-4419651-A1 | Engineering of stratified cell sheets using mesenchymal stem cells | Inactive | 21-Oct-2021 | ||
| US-20240417689-A1 | Engineering of stratified cell sheets using mesenchymal stem cells | Pending | 21-Oct-2021 | ||
| WO-2023069683-A1 | Engineering of stratified cell sheets using mesenchymal stem cells | Inactive | 21-Oct-2021 | C12N5/0655 |
Emmaus Life Sciences Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Emmaus Life Sciences Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Emmaus Life Sciences Investments & Acquisitions (6)
Emmaus Life Sciences’s most recent deal was a PIPE with NeoImmuneTech for . The deal was made on 18-Jun-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| NeoImmuneTech | 18-Jun-2026 | PIPE | Drug Discovery | ||
| Kainos Medicine (Novel IRAK4 Inhibitor) | 12-Oct-2021 | Corporate Asset Purchase | Buildings and Property | ||
| MYnd Analytics | 17-Jul-2019 | Merger/Acquisition | Other Healthcare Services | ||
| Telcon RF Pharmaceutical | 22-Jun-2017 | PIPE | Electrical Equipment | ||
| Kpm Tech | 06-Oct-2016 | PIPE | Industrial Chemicals |
Emmaus Life Sciences ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Emmaus Life Sciences Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Emi Holding | Torrance, CA | 2007 |
Emmaus Life Sciences FAQs
-
When was Emmaus Life Sciences founded?
Emmaus Life Sciences was founded in 2000.
-
Where is Emmaus Life Sciences headquartered?
Emmaus Life Sciences is headquartered in Torrance, CA.
-
What is the size of Emmaus Life Sciences?
Emmaus Life Sciences has 33 total employees.
-
What industry is Emmaus Life Sciences in?
Emmaus Life Sciences’s primary industry is Drug Discovery.
-
Is Emmaus Life Sciences a private or public company?
Emmaus Life Sciences is a Public company.
-
What is Emmaus Life Sciences’s stock symbol?
The ticker symbol for Emmaus Life Sciences is EMMA.
-
What is the current stock price of Emmaus Life Sciences?
As of 12-Nov-2026 the stock price of Emmaus Life Sciences is $0.01.
-
What is the current market cap of Emmaus Life Sciences?
The current market capitalization of Emmaus Life Sciences is $1.05M.
-
What is Emmaus Life Sciences’s current revenue?
The trailing twelve month revenue for Emmaus Life Sciences is $15.5M.
-
Who are Emmaus Life Sciences’s competitors?
Renova Therapeutics, Vanda Pharmaceuticals, Supernus, Dicerna Pharmaceuticals, and Genentech are some of the 46 competitors of Emmaus Life Sciences.
-
What is Emmaus Life Sciences’s annual earnings per share (EPS)?
Emmaus Life Sciences’s EPS for 12 months was -$0.09.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
